Amgen options rights to Xencor's XmAb5871; deal renegotiated
Executive Summary
Amgen Inc. has optioned exclusive global rights to Xencor Inc.’s (antibody engineering specialist) XmAb5871, a late-stage preclinical drug candidate for autoimmune diseases and inflammation.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice